血清HE4、CA125聯(lián)合檢測(cè)對(duì)子宮內(nèi)膜癌診斷價(jià)值的Meta分析
發(fā)布時(shí)間：2019-05-30 02:47
【摘要】：目的：應(yīng)用循證醫(yī)學(xué)的方法對(duì)聯(lián)合檢測(cè)血清人附睪蛋白4(Human Epididymis Protein 4, HE4)和CA125水平在子宮內(nèi)膜癌的診斷價(jià)值進(jìn)行系統(tǒng)評(píng)價(jià),為其診斷子宮內(nèi)膜癌提供評(píng)價(jià)依據(jù)。方法：通過(guò)計(jì)算機(jī)檢索英文數(shù)據(jù)庫(kù),包括Cochrane圖書館、Pubmed數(shù)據(jù)庫(kù)、MEDLINE數(shù)據(jù)庫(kù)、EMBase數(shù)據(jù)庫(kù),中文數(shù)據(jù)庫(kù)包括中國(guó)知網(wǎng)、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)(CBN)、維普中文期刊數(shù)據(jù)庫(kù)及萬(wàn)方學(xué)位論文數(shù)據(jù)庫(kù),同時(shí)手工檢索相關(guān)專業(yè)雜志,并追溯相關(guān)文獻(xiàn)的參考文獻(xiàn),文章語(yǔ)種不限,全面收集聯(lián)合檢測(cè)血清HE4、CA125與金標(biāo)準(zhǔn)(內(nèi)膜病理診斷)比較診斷子宮內(nèi)膜癌的相關(guān)文獻(xiàn),檢索時(shí)限均從創(chuàng)庫(kù)至2015年1月,并由兩位評(píng)價(jià)員分別單獨(dú)根據(jù)設(shè)定好的納入標(biāo)準(zhǔn)及排除標(biāo)準(zhǔn)對(duì)檢索文獻(xiàn)進(jìn)行篩選,對(duì)納入文獻(xiàn)進(jìn)行質(zhì)量評(píng)價(jià)、提取資料及有效數(shù)據(jù),用統(tǒng)計(jì)軟件Revman5.0中的QUADAS量表進(jìn)行質(zhì)量評(píng)價(jià)、用Meta-Disc1.4軟件對(duì)納入研究的診斷試驗(yàn)結(jié)果進(jìn)行Meta分析。結(jié)果：最終納入文獻(xiàn)12篇,樣本量總共1995例,其中經(jīng)過(guò)金標(biāo)準(zhǔn)(子宮內(nèi)膜病理檢查)確診的子宮內(nèi)膜癌患者有1075例、對(duì)照組920例(其中子宮良性病變者有359例、正常婦女有561例)。Meta分析結(jié)果顯示：血清HE4+CA125檢測(cè)診斷子宮內(nèi)膜癌SEN合并=58%[95%CI(0.55,0.61)],SPE合并=92%[95%CI(0.90,0.93)],+LR合并=7.10[95%CI(3.54,14.27)],-LR合并=0.46[95%CI(0.39,0.53)],DOR合并=16.02[95%CI(7.69,33.37)],擬合SROC曲線下面積AUC=0.8696。結(jié)論：研究結(jié)果顯示,血清HE4+CA125檢測(cè)對(duì)子宮內(nèi)膜癌診斷具有較高的敏感度、特異度及AUC值,說(shuō)明聯(lián)合檢測(cè)血清HE4和CA125對(duì)子宮內(nèi)膜癌的診斷有較高的臨床應(yīng)用價(jià)值。
[Abstract]:Objective: to evaluate the diagnostic value of combined detection of serum epididymal protein 4 (Human Epididymis Protein 4 (HE4) and CA125 in endometrial carcinoma by evidence-based medicine (EBM), and to provide evidence for the diagnosis of endometrial carcinoma. Methods: the English database was searched by computer, including Cochrane library, Pubmed database, MEDLINE database, EMBase database, Chinese database including China knowledge Network, Chinese Biomedical Literature Database (CBN),. Weipu Chinese periodical database and Wanfang dissertation database, at the same time manually search the relevant professional magazines, and trace back to the relevant literature references, the language of the article is not limited, comprehensive collection and joint detection of serum HE4, CA125 was compared with gold standard (pathological diagnosis of intima) in the diagnosis of intimal cancer, and the retrieval time was from the database to January 2015. the literature was compared with the gold standard (pathological diagnosis of intima). The retrieval literature was screened by the two evaluators separately according to the established inclusion standard and exclusion standard, and the quality of the included literature was evaluated, and the data and effective data were extracted. The quality of QUADAS scale in statistical software Revman5.0 was evaluated, and the diagnostic test results included in the study were analyzed by Meta software with Meta-Disc1.4 software. Results: a total of 1995 cases were included in 12 articles, of which 1075 cases were diagnosed by gold standard (endometrial pathological examination) and 920 cases in the control group (including 359 cases with benign uterine lesions). There were 561 normal women. Meta-analysis showed that serum HE4 CA125 was used to diagnose endometrial carcinoma with SEN in 58% [95%CI (0.55, 0.61)] and SPE in 92% [95%CI (0.90, 0.93)], and the results of meta-analysis showed that the diagnosis of endometrial carcinoma was 58% [95%CI (0.55, 0.61)], and 92% [95%CI (0.90, 0.93)]. LR merge = 7.10 [95%CI (3.54, 14.27)],-LR merge = 0.46 [95%CI (0.39, 0.53)], DOR merge = 16.02 [95%CI (7.69, 33.37)], fit area AUC=0.8696. under SROC curve Conclusion: the results show that the detection of serum HE4 CA125 has high sensitivity, specificity and AUC value in the diagnosis of endometrial carcinoma, which indicates that the combined detection of serum HE4 and CA125 has high clinical application value in the diagnosis of endometrial carcinoma.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R737.33
本文編號(hào)：2488449
[Abstract]:Objective: to evaluate the diagnostic value of combined detection of serum epididymal protein 4 (Human Epididymis Protein 4 (HE4) and CA125 in endometrial carcinoma by evidence-based medicine (EBM), and to provide evidence for the diagnosis of endometrial carcinoma. Methods: the English database was searched by computer, including Cochrane library, Pubmed database, MEDLINE database, EMBase database, Chinese database including China knowledge Network, Chinese Biomedical Literature Database (CBN),. Weipu Chinese periodical database and Wanfang dissertation database, at the same time manually search the relevant professional magazines, and trace back to the relevant literature references, the language of the article is not limited, comprehensive collection and joint detection of serum HE4, CA125 was compared with gold standard (pathological diagnosis of intima) in the diagnosis of intimal cancer, and the retrieval time was from the database to January 2015. the literature was compared with the gold standard (pathological diagnosis of intima). The retrieval literature was screened by the two evaluators separately according to the established inclusion standard and exclusion standard, and the quality of the included literature was evaluated, and the data and effective data were extracted. The quality of QUADAS scale in statistical software Revman5.0 was evaluated, and the diagnostic test results included in the study were analyzed by Meta software with Meta-Disc1.4 software. Results: a total of 1995 cases were included in 12 articles, of which 1075 cases were diagnosed by gold standard (endometrial pathological examination) and 920 cases in the control group (including 359 cases with benign uterine lesions). There were 561 normal women. Meta-analysis showed that serum HE4 CA125 was used to diagnose endometrial carcinoma with SEN in 58% [95%CI (0.55, 0.61)] and SPE in 92% [95%CI (0.90, 0.93)], and the results of meta-analysis showed that the diagnosis of endometrial carcinoma was 58% [95%CI (0.55, 0.61)], and 92% [95%CI (0.90, 0.93)]. LR merge = 7.10 [95%CI (3.54, 14.27)],-LR merge = 0.46 [95%CI (0.39, 0.53)], DOR merge = 16.02 [95%CI (7.69, 33.37)], fit area AUC=0.8696. under SROC curve Conclusion: the results show that the detection of serum HE4 CA125 has high sensitivity, specificity and AUC value in the diagnosis of endometrial carcinoma, which indicates that the combined detection of serum HE4 and CA125 has high clinical application value in the diagnosis of endometrial carcinoma.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R737.33
【參考文獻(xiàn)】
相關(guān)期刊論文 前7條
1 孫盛梅;肖曉超;張丹鳳;;CA125和HE4聯(lián)合監(jiān)測(cè)在子宮內(nèi)膜癌診斷中的臨床價(jià)值[J];黑龍江醫(yī)藥科學(xué);2014年03期
2 林鶯鶯;陳燕;胡敏華;陳巖松;鄭瑜宏;;術(shù)前HE4單項(xiàng)及聯(lián)合CA125檢測(cè)在子宮內(nèi)膜癌中的臨床價(jià)值[J];現(xiàn)代免疫學(xué);2014年01期
3 吳飛;周慧芹;崔滿華;;聯(lián)合檢測(cè)CA125與HE4在子宮內(nèi)膜癌診斷中的價(jià)值[J];中國(guó)婦幼保健;2011年10期
4 趙靈琴;陳曦;陳魯;陳雅卿;張平;;人附睪分泌蛋白4和CA125聯(lián)合檢測(cè)在子宮內(nèi)膜惡性腫瘤與子宮良性腫瘤鑒別診斷中的價(jià)值[J];中國(guó)癌癥雜志;2012年11期
5 曾憲濤;李勝;雷晉;郭毅;;Review Manager 5軟件在診斷準(zhǔn)確性試驗(yàn)的Meta分析中的應(yīng)用[J];湖北醫(yī)藥學(xué)院學(xué)報(bào);2013年01期
6 張俊;徐志偉;李克;;診斷性試驗(yàn)Meta分析的效應(yīng)指標(biāo)評(píng)價(jià)[J];中國(guó)循證醫(yī)學(xué)雜志;2013年07期
7 於王騏;洪理泉;劉戰(zhàn)峰;;血清HE4檢測(cè)在卵巢癌和子宮內(nèi)膜癌診斷中的應(yīng)用[J];中國(guó)衛(wèi)生檢驗(yàn)雜志;2013年02期
相關(guān)碩士學(xué)位論文 前1條
1 楊勝晗;HE4在子宮內(nèi)膜癌患者血清中的表達(dá)及其與CA125聯(lián)合檢測(cè)的臨床意義[D];蚌埠醫(yī)學(xué)院;2011年
，本文編號(hào)：2488449
本文鏈接：http://sikaile.net/yixuelunwen/fuchankeerkelunwen/2488449.html
最近更新
教材專著
